Questcor sell-off overdone, says CRT Capital CRT Capital said the sell-off in Questcor on concerns Aetna will limit coverage of Acthar is overdone. The firm said Aetna accounts for 5% of Questcor's prescriptions shipped and has made no change to estimates. Share are Buy rated with a $57 price target.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.